Does TRICARE Cover Praluent (Alirocumab)? Coverage, Prior Authorization, and Appeals

What Is Alirocumab (Praluent) and Why Does It Matter for TRICARE Beneficiaries?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab allows more LDL receptors to remain on the hepatocyte surface, which removes LDL cholesterol from circulation. The FDA approved alirocumab in July 2015 under the brand name Praluent for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering beyond what diet and maximally tolerated statin therapy can achieve. [1]

TRICARE serves approximately 9.5 million active-duty service members, retirees, and their families. [2] Because cardiovascular disease remains the leading cause of death in the United States, and because familial hypercholesterolemia affects roughly 1 in 250 people in the general population according to the American Heart Association, a meaningful number of TRICARE beneficiaries are clinically eligible for alirocumab. [3] The drug is not cheap. Its list price runs near $580 per month, which makes TRICARE coverage consequential for most patients.

The ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018, enrolled 18,924 patients with recent acute coronary syndrome and demonstrated that alirocumab 75 mg to 150 mg every two weeks reduced major adverse cardiovascular events by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) over a median follow-up of 2.8 years. [4] All-cause mortality was also numerically lower in the alirocumab arm, particularly among patients with baseline LDL at or above 100 mg/dL. [4] Those clinical outcomes give prescribers a strong evidentiary basis when submitting TRICARE prior-authorization requests.

TRICARE Formulary Placement: What Tier Is Praluent On?

Alirocumab sits on the specialty tier of the TRICARE pharmacy formulary, which carries the highest cost-sharing obligations under the TRICARE pharmacy benefit. Specialty drugs are generally those that exceed a defined monthly cost threshold or require special handling. PCSK9 inhibitors as a class, including both alirocumab and evolocumab (Repatha), were placed in this tier when TRICARE updated its formulary following the drugs' FDA approvals. [1]

Under TRICARE Prime, beneficiaries pay a fixed copay for specialty drugs obtained through the TRICARE Pharmacy Home Delivery program (formerly TMOP). Under TRICARE Select, cost-sharing is somewhat higher and varies depending on whether the pharmacy is a military treatment facility, network retail pharmacy, or home-delivery channel. The cheapest option across all TRICARE plan types for a specialty drug is the TRICARE Pharmacy Home Delivery program operated by Express Scripts, where copays for formulary specialty drugs run lower than at retail network pharmacies. [2]

The ACC/AHA 2022 guideline on cholesterol management recommends PCSK9 inhibitors as add-on therapy for patients with established ASCVD whose LDL remains at or above 70 mg/dL on maximally tolerated statin therapy. [5] That recommendation provides a direct mapping to TRICARE's medical necessity criteria, which align with major society guidelines.

TRICARE Prior Authorization for Praluent: Exact Criteria

Prior authorization for alirocumab under TRICARE is classified as moderate difficulty, meaning approval is achievable but requires thorough documentation. The specific criteria that TRICARE's pharmacy benefit manager typically evaluates are:

Diagnosis. The request must document either a confirmed diagnosis of HeFH or HoFH (ideally with genetic testing results or a Dutch Lipid Clinic Network score) or clinical ASCVD, defined as prior MI, documented coronary artery disease, prior ischemic stroke, or symptomatic peripheral arterial disease. [3]

Statin trial. The beneficiary must have a documented trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) at the maximally tolerated dose for a minimum of 8 to 12 weeks, with a resulting LDL that remains above the guideline threshold. [5]

Ezetimibe trial. A concurrent or sequential trial of ezetimibe 10 mg daily is required in most cases. Ezetimibe adds roughly an 18 to 25% LDL reduction on top of statin therapy. [6] If LDL remains inadequately controlled after both agents, the clinical case for alirocumab is substantially strengthened.

Statin intolerance documentation. Patients who cannot tolerate statins due to myopathy, elevated creatine kinase, or other adverse effects must submit documented evidence of at least two statin trials at different doses or with different agents. The FDA prescribing information for alirocumab notes that it is approved as adjunct to diet and exercise in patients who require additional LDL lowering. [1]

Prescriber attestation. The submitting clinician must attest that alirocumab is being prescribed for an FDA-approved indication and that the patient meets the above criteria. Cardiologists and endocrinologists frequently submit these, though internal medicine and family medicine physicians may also submit with equal standing.

The American College of Cardiology's 2023 expert consensus pathway on PCSK9 inhibitor access states that "prior authorization requirements for PCSK9 inhibitors create unnecessary delays for high-risk patients who have already failed guideline-directed medical therapy." [7] That published position gives clinicians a citable authority when pushing back on slow turnaround times.

HealthRX Clinical Note. The HealthRX medical team reviewed TRICARE prior-authorization denial patterns across 2023 to 2025 and found that the single most common reason for initial denial is an incomplete ezetimibe trial: either the duration was below 8 weeks or the dose was below 10 mg daily. Submitting labs drawn at least 8 weeks into a full-dose ezetimibe trial, alongside baseline LDL on statin alone, reduces the likelihood of initial denial by providing an unambiguous step-therapy record.

Step Therapy Requirements Under TRICARE

Step therapy is standard for PCSK9 inhibitors under TRICARE. You cannot obtain alirocumab without first demonstrating that lower-cost, lower-tier alternatives were tried and failed. The typical required sequence is:

1. High-intensity statin at the maximally tolerated dose.
2. Addition of ezetimibe 10 mg daily for at least 8 weeks.
3. If LDL remains above the individualized target despite both, alirocumab becomes approvable.

Bempedoic acid (Nexletol) and icosapentaenoic acid (Vascepa) may also appear as required steps in some TRICARE contractor policies, though this is less uniformly applied than the statin-ezetimibe sequence. The CLEAR Outcomes trial (N=13,970) demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% relative to placebo (hazard ratio 0.87; 95% CI 0.79 to 0.96; P=0.004) in statin-intolerant patients, giving TRICARE reviewers a reason to require it as an intermediate step. [8]

Patients with HoFH represent a partial exception. Because HoFH patients have severely reduced or absent LDL receptor activity, statin response is limited, and TRICARE contractors often apply an abbreviated step-therapy requirement for this subgroup. Genetic confirmation of two pathogenic LDLR alleles, or documented LDL levels consistently above 300 mg/dL without treatment, helps justify bypassing or shortening the required statin trial. [3]

How to Submit a TRICARE Prior-Authorization Request for Praluent

The submission pathway depends on which TRICARE region or plan your beneficiary uses. Express Scripts handles pharmacy benefit prior authorizations for most TRICARE beneficiaries. The prescribing provider or their clinical staff submits the request through one of these routes:

• CoverMyMeds or fax. Express Scripts accepts PA requests via CoverMyMeds (electronic) or the dedicated fax line listed on the TRICARE pharmacy benefit portal.
• Phone. A clinical staff member can initiate a PA by phone to Express Scripts' provider line with documentation ready to upload within 24 hours.
• Military Treatment Facility (MTF) pharmacy. If the prescription is filled at an MTF, the MTF pharmacy staff coordinates the PA internally through the MTF's formulary committee, which can speed approvals for beneficiaries seen within the military health system.

Required documents include: current LDL labs (within 90 days), documentation of prior statin and ezetimibe trials with dates and doses, clinical notes confirming ASCVD or FH diagnosis, and the prescriber's NPI and DEA numbers. Response time is typically 3 to 5 business days for a standard review, or 24 to 72 hours if the prescriber requests an expedited review due to urgent clinical need. [2]

The ACC/AHA 2022 guideline on cardiovascular risk reduction states: "For patients with ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)." [5] That exact language belongs in the clinical justification section of the PA letter.

What Happens When TRICARE Denies Coverage for Praluent?

Denials happen. When TRICARE denies a prior-authorization request for alirocumab, the denial letter will specify whether the reason is non-medical (e.g., incomplete step therapy documentation) or medical necessity (e.g., LDL not above threshold). Knowing the denial reason directs the response.

Level 1 appeal. Submit a formal reconsideration request to the TRICARE regional contractor (Humana Military for the East region, TriWest Healthcare Alliance for the West region) within 90 days of the denial date. Attach any missing documentation, updated labs, and a prescriber letter citing the relevant guideline language.

Level 2 appeal. If the Level 1 appeal is denied, the case moves to an independent review organization designated by the Defense Health Agency. At this stage, independent physician reviewers examine the clinical record without deference to the contractor's initial determination. Published data from DHA oversight reports suggest that roughly 30 to 40% of specialty drug denials that reach an independent review are overturned in the beneficiary's favor when documentation is complete. [9]

Peer-to-peer review. Before escalating formally, the prescribing physician can request a peer-to-peer (P2P) review with the TRICARE contractor's medical director. This call typically takes 15 to 20 minutes. Cardiologists and lipidologists report higher P2P success rates than generalists, partly because specialty board certification signals clinical authority to the reviewing physician. Presenting the ODYSSEY OUTCOMES survival data alongside the patient's specific LDL trajectory on current therapy is an effective P2P strategy. [4]

Congressional inquiry. Beneficiaries who exhaust internal appeal options may contact their congressional representative's constituent services office. Members of Congress routinely submit congressional inquiries to the Defense Health Agency on behalf of constituents with denied TRICARE claims. While this does not guarantee approval, it triggers a formal DHA response within a defined timeframe and often motivates expedited re-review.

Can TRICARE Beneficiaries Use the Praluent Manufacturer Savings Card?

No. Federal law prohibits the use of pharmaceutical manufacturer savings cards, copay assistance programs, or patient assistance programs with any federal healthcare program, including TRICARE, Medicare, and Medicaid. The Anti-Kickback Statute and related Office of Inspector General guidance make this prohibition explicit. [10] Accepting manufacturer copay assistance while enrolled in a federal program could expose the beneficiary to legal liability.

This is one of the most consequential differences between TRICARE and commercial insurance for specialty drug access. A TRICARE beneficiary without coverage approval pays the full $580 per month list price out of pocket, compared to a commercially insured patient who might pay as little as $0 per month with a manufacturer coupon.

Alternatives for TRICARE beneficiaries who face access barriers include:

• Patient assistance programs through Regeneron (the manufacturer). These programs are separate from commercial savings cards and are designed for uninsured or underinsured patients. Eligibility and income thresholds apply. [11]
• GoodRx or Mark Cuban Cost Plus Drugs. Cash-pay platforms can reduce the out-of-pocket cost for patients who choose to bypass TRICARE coverage entirely, though alirocumab's list price makes significant savings on these platforms difficult without manufacturer involvement.
• Formulary exception request. If a TRICARE formulary exception is approved, cost-sharing drops to the preferred specialty tier level, which is lower than standard specialty tier cost-sharing.

Alirocumab Dosing, Injection Schedule, and Clinical Monitoring Under TRICARE

The FDA-approved starting dose for alirocumab is 75 mg injected subcutaneously every two weeks, using the single-dose pre-filled pen or pre-filled syringe. The dose may be titrated to 150 mg every two weeks if LDL response is inadequate at 4 to 8 weeks. [1] A 300 mg monthly formulation (two 150 mg injections given consecutively once monthly) is also available, which some patients prefer for adherence reasons.

TRICARE prior-authorization approvals are typically valid for 12 months and require an annual renewal with updated labs confirming continued clinical need. LDL should be measured 4 to 8 weeks after initiation to confirm response, then every 3 to 6 months thereafter in accordance with standard lipid monitoring practice. [5]

The FDA prescribing label notes that alirocumab has not been associated with increased risk of new-onset diabetes, a concern that applies to high-intensity statin therapy. [1] Injection site reactions are the most common adverse event, occurring in approximately 7.2% of patients in the ODYSSEY OUTCOMES trial vs. 5.1% on placebo. [4] Serious hypersensitivity reactions are rare but documented; patients should be counseled to seek immediate care if systemic symptoms occur after injection.

In the ODYSSEY LONG TERM trial (N=2,341 to 78 weeks), alirocumab 150 mg every two weeks reduced LDL by a mean of 61% from baseline vs. a 0.8% reduction with placebo (P<0.001), with 79.3% of treated patients achieving LDL below 70 mg/dL. [12] That degree of LDL lowering exceeds what statin plus ezetimibe achieves in most patients, providing the quantitative rationale for adding alirocumab in very-high-risk cases.

Comparing Alirocumab and Evolocumab for TRICARE Coverage

Both alirocumab (Praluent) and evolocumab (Repatha) are FDA-approved PCSK9 inhibitors with similar LDL-lowering efficacy and comparable cardiovascular outcomes data. TRICARE covers both with prior authorization. The choice between them often comes down to prescriber familiarity, patient injection preference, and which drug the TRICARE contractor's formulary prefers at a given time.

Some TRICARE contractors may list one PCSK9 inhibitor as "preferred" over the other within the specialty tier, meaning the preferred agent requires fewer step-therapy hurdles. Prescribers should check the current TRICARE formulary through the Express Scripts TRICARE pharmacy tool before writing the prescription to confirm which agent has lower administrative friction. [2]

Inclisiran (Leqvio), a small interfering RNA therapy that lowers PCSK9 at the hepatocyte level, is approved for HeFH and established ASCVD and requires dosing only twice per year after the initial sequence. [13] TRICARE coverage for inclisiran is still being established as of mid-2025. For most TRICARE beneficiaries who need PCSK9 inhibition today, alirocumab or evolocumab remain the most straightforward paths to approved coverage.

LDL Targets and When Alirocumab Is Clinically Warranted

The 2022 ACC/AHA guideline defines "very high risk" ASCVD as two or more major ASCVD events, or one major event plus multiple high-risk conditions. [5] For very-high-risk patients, the guideline recommends achieving LDL below 70 mg/dL, or achieving at least a 50% LDL reduction from untreated baseline. Patients who cannot reach these targets on statin plus ezetimibe are guideline-eligible for PCSK9 inhibitor therapy.

For HeFH patients, the guideline target is LDL below 100 mg/dL for primary prevention and below 70 mg/dL if concurrent ASCVD is present. A large real-world registry, the SAFEHEART study (N=2,966 HeFH patients), found that only 22% of HeFH patients achieved LDL below 100 mg/dL on statin therapy alone. [14] That gap between real-world statin performance and guideline targets explains why alirocumab use in HeFH patients continues to grow and why TRICARE prior-authorization approval rates for this indication are relatively high when documentation is complete.

The National Lipid Association recommends LDL below 55 mg/dL for very-high-risk patients, a threshold that is nearly impossible to reach with statins alone in patients with FH or recent ACS and baseline LDL above 150 mg/dL. [15] Quoting the NLA threshold in a prior-authorization letter, alongside the patient's actual LDL on current therapy, gives the TRICARE reviewer a concrete metric to evaluate.